Cargando…

Hypophosphatemic effect of niacin extended release in ischemic kidney disease

Ischemic nephropathy is an emerging cause of end stage renal disease, associated with many co-morbidities especially cardiovascular disease risk and derangement in calcium-phosphorus homeostasis resulting in hyperphosphatemia, influencing bones, a characteristic of advancing chronic kidney disease....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yasmeen, Ghazala, Dawani, Manohar Lal, Mahboob, Tabassum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763466/ https://www.ncbi.nlm.nih.gov/pubmed/26933406 http://dx.doi.org/10.17179/excli2015-537

Ejemplares similares

Effect of Extended Release Niacin on Cardiovascular Events and Kidney Function in Chronic Kidney Disease: A Post-Hoc Analysis of the AIM-HIGH Trial
por: Kalil, Roberto S., et al.
Publicado: (2015)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome
por: Chow, Dominic C, et al.
Publicado: (2008)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Niacin in patients with chronic kidney disease: Is it effective and safe?
por: Park, Cheol Whee
Publicado: (2013)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
por: Hu, Miao, et al.
Publicado: (2015)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
por: Robinson, Jennifer G
Publicado: (2009)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
por: Lyseng-Williamson, Katherine A.
Publicado: (2012)

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
por: Insull, William, et al.
Publicado: (2010)

The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a)
por: Helmbold, Alan F., et al.
Publicado: (2010)

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients
por: Yadav, Rahul, et al.
Publicado: (2015)

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
por: Guyton, John R., et al.
Publicado: (2012)

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
por: Michailov, Galin V., et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease
por: Jin Kang, Hyo, et al.
Publicado: (2013)

Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series
por: Hanna, Christian, et al.
Publicado: (2022)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
por: Bays, Harold E, et al.
Publicado: (2015)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
por: Farnier, Michel, et al.
Publicado: (2014)

Hypophosphatemic rickets
por: Jagtap, Varsha S., et al.
Publicado: (2012)

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
por: Toth, Peter P, et al.
Publicado: (2012)

Niacin in Maize
por: Burkholder, Paul R., et al.
Publicado: (1944)

Three Novel Mutations in the PHEX Gene in Chinese Subjects with Hypophosphatemic Rickets Extends Genotypic Variability
por: Jap, Tjin-Shing, et al.
Publicado: (2011)

Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial
por: Chong, Raymond, et al.
Publicado: (2021)

Approach to Hypophosphatemic Rickets
por: Ackah, Sarah A, et al.
Publicado: (2022)

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes
por: Brinton, Eliot A., et al.
Publicado: (2016)

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBI-TER 2
por: Taylor, Allen J, et al.
Publicado: (2007)

Evaluating the Release of Different Commercial Orally Modified Niacin Formulations In Vitro
por: Chbib, Christiane, et al.
Publicado: (2023)

HYPOPHOSPHATEMIC RICKETS: CASE REPORT
por: Maia, Marta Liliane de Almeida, et al.
Publicado: (2018)

Osteocytes and the pathogenesis of hypophosphatemic rickets
por: Yamazaki, Miwa, et al.
Publicado: (2022)

The effect of niacin on serum phosphorus levels in dialysis patients
por: Edalat-Nejad, M., et al.
Publicado: (2012)

Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial
por: Paolini, J F, et al.
Publicado: (2008)

Nationwide Turkish Cohort Study of Hypophosphatemic Rickets
por: Şıklar, Zeynep, et al.
Publicado: (2020)

Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson’s disease symptoms without side effects
por: Wakade, Chandramohan, et al.
Publicado: (2015)

Design and Evaluation of Niacin Microspheres
por: Maravajhala, Vidyavathi, et al.
Publicado: (2009)

Ocular Effects of Niacin: A Review of the Literature
por: Domanico, Daniela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ohv1fr965bn05s111gemqukdd4